Abstract
The pyrimidine nucleoside analog, 1-β-D-arabinofuranosylcytosine (ara-C), is the most effective drug for the successful treatment of adult acute myelogenous leukemia (1). The cytotoxic activity of ara-C is dependent upon its intracellular conversion to the active 5′-triphosphate ara-CTP. Ara-CTP competes with dCTP in the inhibition of DNA polymerase, but its incorporation into DNA indicates that it also serves as a substrate for the enzyme. These actions are associated with the cytotoxicity of the drug. However, ara-CTP also participates as an analog in the intermediary metabolism of phospholipids and is glycoprotein synthesis. In fact, ara-CTP is required for all of the known mechanisms of ara-C-induced cell killing.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
M.J. Keating, K.B. McCredie, G.P. Bodey, T.L. Smith, E. Gehan, and E.J. Freireich, Improved prospects for long-term survival in adults with acute myelogenous leukemia, J. Amer. Med. Assoc., 248: 2481, 1982.
W. Plunkett, S. Iacoboni, E. Estey, L. Danhauser, J.O. Liliemark, and M.J. Keating, Pharmacologically directed ara-C therapy for refractory leukemia, Sem. Oncol. 12: (Suppl 3), 20, 1985.
B. Barlogie, W. Plunkett, M. Raber, J. Latreille, M. Keating and K. McCredie, In vivo cellular kinetic and pharmacological studies of 1-β-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia, Cancer Res., 41: 1227, 1981.
M. Keating, T. Smith, K. McCredie, E. Estey, and E. J. Freireich, Successful introduction of a new m-AMSA containing regimen in acute leukemia, Proc. Amer. Soc. Clin. Oncol. 2: 174, 1983.
W. Plunkett, S. Chubb, and B. Barlogie, Simultaneous determination of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 3-deazauridine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography. J. Chromat ogr., 221: 445, 1980.
R. Meyn, W. Plunkett, and E. Estey, Quantitation of DNA strand breaks in circulating blasts from leukemia patients during therapy with m-AMSA, Proc. Amer. Assn. Cancer Res., 26: 161, 1985.
W. Plunkett, R.S. Benjamin, M.J. Keating and E.J. Freireich, Modulation of 9-β-D-arabinofuranosyladenine 5′-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2′-deoxycoformycin during therapy with 9-β-D-arabinofuranosyladenine, Cancer Res 42: 2092, 1982.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Plunkett, W., Keating, M. (1986). Effect of m-Amsa on the Cellular Pharmacology of Ara-CTP in Human Leukemic Cells During Therapy with High-Dose Ara-C. In: Nyhan, W.L., Thompson, L.F., Watts, R.W.E. (eds) Purine and Pyrimidine Metabolism in Man V. Advances in Experimental Medicine and Biology, vol 195B. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-1248-2_26
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1248-2_26
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-1250-5
Online ISBN: 978-1-4684-1248-2
eBook Packages: Springer Book Archive